CME Group Inc (CME)
Official siteFINANCIAL SERVICES • FINANCIAL DATA & STOCK EXCHANGES • NASDAQ
Market Cap: $114.31B
Last updated: Nov 17, 2026 at 4:40 PM ET
CME Group Inc (CME) Statistics
CME Group (CME) has a market cap of $114.31B and an enterprise value of $115.54B. It kept 63.33% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 1.07% above the market cap, as debt exceeds cash.
| Market Cap | $114.31B |
|---|---|
| Enterprise Value | $115.54B |
| Latest price (Nov 17, 2026) | $311.56 |
Key Dates
The next earnings report is expected on Feb 2, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Dec 11, 2026.
| Next Earnings Date | Feb 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 21, 2026 |
| Next Ex-Dividend Date | Dec 11, 2026 |
| Next Payment Date | Dec 30, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 16.0x and 4.2x. Its year-end P/E ranged from 21.1x to 34.1x from 2016 to 2025.
| P/E Ratio | 25.7x |
|---|---|
| Forward P/E | 24.9x |
| P/S Ratio | 16.0x |
| Forward P/S | 16.1x |
| P/B Ratio | 4.2x |
| P/FCF Ratio | 25.7x |
| P/OCF Ratio | 25.8x |
| PEG Ratio | 3.0 |
Enterprise Valuation
Counting debt and cash, the company is valued at 26.0x free cash flow.
| EV / Earnings | 26.2x |
|---|---|
| EV / Sales | 16.6x |
| EV / FCF | 26.0x |
Price Statistics
The stock is up 13.05% over 52 weeks and trades 8.39% above its 50-day average.
| Beta (1Y) | -0.29 |
|---|---|
| 52-Week Change | +13.05% |
| 1-Month Change | +6.14% |
| 3-Month Change | +17.27% |
| 6-Month Change | +4.05% |
| 5-Year Change | +37.45% |
| 10-Year Change | +202.84% |
| Total Return (1Y) | +17.15% |
| Total Return (3Y CAGR) | +18.21% |
| Total Return (5Y CAGR) | +11.09% |
| Return vs SPY (1Y) | +3.82% |
| Max Drawdown (1Y) | -31.39% |
| Max Drawdown (3Y) | -31.39% |
| Sharpe Ratio (1Y) | 0.58 |
| Correlation with SPY (1Y) | -0.16 |
| 50-Day Average | $287.44 |
| 200-Day Average | $279.68 |
| 52-Week Range | $217.29 to $321.39 |
| RSI (14 Days) | 60.9 |
| Average Volume (20 Days) | 1.89M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.02x current liabilities, and total debt is 0.13x shareholder equity.
| Current Ratio | 1.02x |
|---|---|
| Quick Ratio | 1.02x |
| Debt / Equity | 0.13x |
| Debt / FCF | 0.79x |
| Interest Coverage | 1.69x |
Returns and Efficiency
Return on invested capital is -1.17% over the last 12 months, against a 5-year average of 1.31%.
| Return on Equity (ROE) | 16.63% |
|---|---|
| Return on Assets (ROA) | 2.30% |
| Return on Invested Capital (ROIC) | -1.17% |
| ROE (5Y Average) | 11.84% |
| ROA (5Y Average) | 2.00% |
| ROIC (5Y Average) | 1.31% |
| Asset Turnover | 0.04x |
| Receivables Turnover | 9.05x |
Taxes
Income tax took 23.49% of pretax income over the last 12 months.
| Income Tax (TTM) | $1.36B |
|---|---|
| Effective Tax Rate | 23.49% |
Scores
CME has an Altman Z-Score of 0.50, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.50 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $6.97B over the last 12 months is up 8.99% from the 12 months before.
| Revenue | $6.97B |
|---|---|
| Revenue Growth (YoY) | +8.99% |
| Gross Profit | $6.04B |
| Operating Income | $4.58B |
| Pretax Income | $5.77B |
| Net Income | $4.42B |
| Reported EPS (TTM) | $12.14 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 13.83% of the $192.09B in total assets.
| Cash and Equivalents | $2.20B |
|---|---|
| Total Debt | $3.43B |
| Net Debt | $1.23B |
| Net Debt Per Share | $3.43 |
| Working Capital | $3.03B |
| Shareholder Equity | $26.56B |
| Book Value Per Share | $74.19 |
| Tangible Book Value | -$3.56B |
| Total Assets | $192.09B |
| Total Liabilities | $165.53B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $93.70M of capital spending, operating cash flow left $4.33B of free cash flow.
| Operating Cash Flow | $4.43B |
|---|---|
| Capital Expenditures | $93.70M |
| Free Cash Flow | $4.33B |
| FCF Per Share | $12.05 |
| Depreciation and Amortization | $333.30M |
| Dividends Paid | $4.09B |
| Share Repurchases | $2.02B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 65.66%, against a 5-year average of 61.41%.
| Gross Margin | 86.63% |
|---|---|
| Operating Margin | 65.66% |
| Pretax Margin | 82.78% |
| Net Margin | 63.33% |
| FCF Margin | 62.15% |
| Gross Margin (5Y Average) | 84.90% |
| Operating Margin (5Y Average) | 61.41% |
| Net Margin (5Y Average) | 57.53% |
Growth
Revenue grew 9.11% a year over 3 years, and EPS 12.00% a year.
| Revenue Growth (3Y CAGR) | +9.11% |
|---|---|
| Revenue Growth (5Y CAGR) | +5.95% |
| EPS Growth (3Y CAGR) | +12.00% |
| EPS Growth (5Y CAGR) | +10.74% |
| FCF Growth (3Y CAGR) | +12.23% |
| FCF Growth (5Y CAGR) | +10.74% |
| Operating Income Growth (3Y CAGR) | +11.93% |
| Book Value Per Share Growth (2Y CAGR) | +3.58% |
Dividends and Yields
CME pays out 31.14% of earnings as dividends.
| Dividend Per Share (Annual) | $5.20 |
|---|---|
| Dividend Yield | 1.67% |
| Dividend Growth (3Y CAGR) | +7.72% |
| Dividend Growth (5Y CAGR) | +8.02% |
| Payout Ratio | 31.14% |
| FCF Payout Ratio | 94.29% |
| Earnings Yield | 3.89% |
| FCF Yield | 3.88% |
| Buyback Yield | 1.81% |
| Shareholder Yield | 5.47% |
Stock Splits
The last split was a 5-for-1 forward split on Jul 23, 2012.
| Last Split Date | Jul 23, 2012 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 5:1 |
Peer Position
Against 10 similar companies, CME has the 6th highest P/E.
P/E RatioPeer median 25.1x
P/S RatioPeer median 6.1x
ROICPeer median 14.27%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +9.60%
Dividend YieldPeer median 1.05%
| P/E Ratio | 25.7x vs 25.1x median |
|---|---|
| P/S Ratio | 16.0x vs 6.1x median |
| ROIC | -1.17% vs 14.27% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +8.99% vs +9.60% median |
| Dividend Yield | 1.67% vs 1.05% median |
Analyst Forecast
Consensus estimates put revenue growth at 7.02% and EPS growth at 8.70% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +7.02% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +8.70% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CME
What is CME's market cap?
CME Group has a market cap of $114.31B. Its enterprise value, which adds debt and subtracts cash, is $115.54B.
What is CME's P/E ratio?
CME Group has a trailing P/E ratio of 25.7x and a forward P/E of 24.9x.
How many shares of CME are outstanding?
CME Group has 358.02M shares outstanding. The count is down 0.46% from a year earlier.
Does CME pay a dividend?
Yes. CME Group pays $5.20 a share a year, a dividend yield of 1.67%.
How much debt does CME have?
CME Group has $3.43B of total debt and $2.20B of cash and equivalents, a net debt position of $1.23B.
CME pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors